Andrew Butcher is speaking on “Balancing cost effectiveness with economics – alleviate funding constraints on HTA approved drugs by managing diverging stakeholder perspectives.” CRA is also sponsoring the conference.
For more information on the event, click here.
Disparities in screening and diagnosis for triple negative breast cancer
Gilead Sciences asked Charles River Associates and Tigerlily Foundation to examine the extent to which policies associated with triple negative breast cancer...